Compare LAND & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAND | CLLS |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.3M | 374.2M |
| IPO Year | 2013 | 2007 |
| Metric | LAND | CLLS |
|---|---|---|
| Price | $11.14 | $3.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 848.7K | 40.8K |
| Earning Date | 02-24-2026 | 03-12-2026 |
| Dividend Yield | ★ 5.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $67,936,000.00 | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | $4.39 | $20.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $8.47 | $1.10 |
| 52 Week High | $11.93 | $5.48 |
| Indicator | LAND | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 62.36 | 44.43 |
| Support Level | $10.81 | $3.44 |
| Resistance Level | $11.33 | $3.98 |
| Average True Range (ATR) | 0.38 | 0.20 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 74.19 | 36.30 |
Gladstone Land Corp is an externally-managed, agricultural REIT. It is mainly in the business of owning and leasing farmland. It manages operations in one reporting segment. It is focused on the ownership of high-quality farms and farm-related properties that are leased on a triple-net basis to tenants with a good operating history and deep farming resources. The farmland is predominantly concentrated in locations where farmers are able to grow either fresh produce annual row crops (e.g., certain berries and vegetables), which are typically planted and harvested annually, or certain permanent crops (e.g., almonds, blueberries, pistachios, and wine grapes). To a much lesser extent, it also own farms that grow certain commodity crops (e.g., corn and beans).
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.